Question

Pharmicon, Inc., a pharmaceutical firm, discovered a complete cure for the common cold. The medicine could be put into a pill that would be taken once a day for a week. Knowing these results, directors of Pharmicon decided to delay the press release and bought thousands of shares of Pharmicon stock. After the purchases, Pharmicon issued a press release about the pill. The price of the stock skyrocketed. When the SEC found out about the purchases and the delay in the press release, it sued Pharmicon for violating Rule 10b-5. Based on the decision in Case 41.1, SEC v. Texas Gulf Sulphur Co., the court in this case would most likely rule in favor of
a. the SEC, because the information about the cure was material and was not disclosed to the public prior to the directors' purchase of the stock.
b. Pharmicon, because the information was not material.
c. the SEC, because owning company stock is a conflict of interest for the directors.
d. Pharmicon, because they issued a press release to the public.

Answer

This answer is hidden. It contains 1 characters.